TY - JOUR
T1 - MicroRNA expression and function in prostate cancer
T2 - A review of current knowledge and opportunities for discovery
AU - Kumar, Binod
AU - Lupold, Shawn
N1 - Funding Information:
ACKNOWLEDGMENTS: Funding for this manuscript was supported by grants from the National Institutes of Health 5R01CA143299, 5P50CA058236, and the Patrick C Walsh Prostate Cancer Research Fund.
PY - 2016/7
Y1 - 2016/7
N2 - MicroRNAs (miRNAs) are well-conserved noncoding RNAs that broadly regulate gene expression through posttranscriptional silencing of coding genes. Dysregulated miRNA expression in prostate and other cancers implicates their role in cancer biology. Moreover, functional studies provide support for the contribution of miRNAs to several key pathways in cancer initiation and progression. Comparative analyses of miRNA gene expression between malignant and nonmalignant prostate tissues, healthy controls and prostate cancer (PCa) patients, as well as less aggressive versus more aggressive disease indicate that miRNAs may be future diagnostic or prognostic biomarkers in tumor tissue, blood, or urine. Further, miRNAs may be future therapeutics or therapeutic targets. In this review, we examine the miRNAs most commonly observed to be de-regulated in PCa gene expression analyses and review the potential contribution of these miRNAs to important pathways in PCa initiation and progression.
AB - MicroRNAs (miRNAs) are well-conserved noncoding RNAs that broadly regulate gene expression through posttranscriptional silencing of coding genes. Dysregulated miRNA expression in prostate and other cancers implicates their role in cancer biology. Moreover, functional studies provide support for the contribution of miRNAs to several key pathways in cancer initiation and progression. Comparative analyses of miRNA gene expression between malignant and nonmalignant prostate tissues, healthy controls and prostate cancer (PCa) patients, as well as less aggressive versus more aggressive disease indicate that miRNAs may be future diagnostic or prognostic biomarkers in tumor tissue, blood, or urine. Further, miRNAs may be future therapeutics or therapeutic targets. In this review, we examine the miRNAs most commonly observed to be de-regulated in PCa gene expression analyses and review the potential contribution of these miRNAs to important pathways in PCa initiation and progression.
KW - miRNA
KW - noncoding RNA
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84977602215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977602215&partnerID=8YFLogxK
U2 - 10.4103/1008-682X.177839
DO - 10.4103/1008-682X.177839
M3 - Review article
C2 - 27056344
AN - SCOPUS:84977602215
SN - 1008-682X
VL - 18
SP - 559
EP - 567
JO - Asian Journal of Andrology
JF - Asian Journal of Andrology
IS - 4
ER -